Induction of apoptosis of lung and esophageal cancer cells treated with the combination of histone deacetylase inhibitor (trichostatin A) and protein kinase C inhibitor (calphostin C)

Journal of Thoracic and Cardiovascular Surgery

Volumn 129, Issue 1, 2005, Pages 53-63

  Maxhimer, Justin B ^a,b   Reddy, Rishindra M ^a   Zuo, Jingtong ^a   Cole Jr , George W ^a   Schrump, David S ^a   Nguyen, Dao M ^a  

^a Ctr Cancer Res   (United States)

^b Bethesda   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CALPHOSTIN C; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE C INHIBITOR; PROTEIN P21; TRICHOSTATIN A;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENZYMATIC ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS CANCER; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LUNG CANCER; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CELL SURVIVAL; DRUG THERAPY, COMBINATION; ESOPHAGEAL NEOPLASMS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; LUNG NEOPLASMS; NAPHTHALENES; NF-KAPPA B; ONCOGENE PROTEIN P21(RAS); PROBABILITY; PROTEIN KINASE C; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 11144284854     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2004.07.051     Document Type: Article

References (22)

1. D.R. Spigel, F.A. Greco Chemotherapy in metastatic and locally advanced non-small cell lung cancer Semin Surg Oncol 21 2003 98 110
2. L. Crino, F. Cappuzzo Present and future treatment of advanced non-small cell lung cancer Semin Oncol 29 suppl 9 2002 9 16
3. F.A. Shepherd Treatment of advanced non-small cell lung cancer Semin Oncol 21 suppl 7 1994 7 18
4. M. Koshy, N. Esiashvilli, J.C. Landry, C.R. Thomas Jr, R.H. Matthews Multiple management modalities in esophageal cancer: epidemiology, presentation and progression, work-up, and surgical approaches Oncologist 9 2004 137 146
5. D.M. Vigushin, R.C. Coombes Histone deacetylase inhibitors in cancer treatment Anticancer Drugs 13 2002 1 13
6. X. Yu, Z.S. Guo, M.G. Marcu, L. Neckers, D.M. Nguyen, G.A. Chen, D.S. Schrump Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228 J Natl Cancer Inst 94 2002 504 513
7. P.A. Marks, R.A. Rifkind, V.M. Richon, R. Breslow Inhibitors of histone deacetylase are potentially effective anticancer agents Clin Cancer Res 7 2001 759 760
8. G. Elaut, G. Torok, M. Vinken, G. Laus, P. Papeleu, D. Tourwe Major phase I biotransformation pathways of Trichostatin a in rat hepatocytes and in rat and human liver microsomes Drug Metab Dispos 30 2002 1320 1328
9. K. Nakano, T. Mizuno, Y. Sowa, T. Orita, T. Yoshino, Y. Okuyama, T. Fujita Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line J Biol Chem 272 1997 22199 22206
10. M.W. Mayo, C.E. Denlinger, R.M. Broad, F. Yeung, E.T. Reilly, Y. Shi, D.R. Jones Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway J Biol Chem 278 2003 18980 18989
11. Q. Wang, X. Wang, B.M. Evers Induction of cIAP-2 in human colon cancer cells through PKC delta/NF-kappa B J Biol Chem 278 2003 51091 51099
12. H.J. Shin, K.H. Baek, A.H. Jeon, S.J. Kim, K.L. Jang, Y.C. Sung Inhibition of histone deacetylase activity increases chromosomal instability by the aberrant regulation of mitotic checkpoint activation Oncogene 22 2003 3853 3858
13. D.M. Vigushin, R.C. Coombes Histone deacetylase inhibitors in cancer treatment Anticancer Drugs 13 2002 1 13
14. M.W. Mayo, A.S. Baldwin The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance Biochim Biophys Acta 1470 2000 M55 62
15. W.S. El-Deiry, T. Tokino, V.E. Velculescu, D.B. Levy, R. Parsons, J.M. Trent WAF1, a potential mediator of p53 tumor suppression Cell 75 1993 817 825
16. D.M. Nguyen, W.D. Schrump, G.A. Chen, W. Tsai, P. Nguyen, J.B. Trepel Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells Clin Cancer Res 10 2004 1813 1825
17. D.M. Nguyen, W.D. Schrump, W.S. Tsai, A. Chen, J.H.4th Stewart, and F. Steiner Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway J Thorac Cardiovasc Surg 125 2003 1132 1142
18. R.R. Rosato, J.A. Almenara, S. Grant The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1 Cancer Res 63 2003 3637 3645
19. J.W. Han, S.H. Ahn, Y.K. Kim, G.U. Bae, J.W. Yoon, S. Hong, H.Y. Lee Activation of p21(WAF1/Cip1) transcription through Sp1 sites by histone deacetylase inhibitor apicidin: involvement of protein kinase C J Biol Chem 276 2001 42084 42090
20. Catley MC, Cambridge LM, Nasuhara Y, Ito K, Chivers JE, Beaton A, et al. Inhibitors of protein kinase C (PKC) prevent activated transcription: role of events downstream of NF-kappaB DNA binding. J Biol Chem. 2004;279:18457-66.
21. W.K. Kelly, V.M. Richon, O. O'Connor, T. Curley, B. MacGregor-Curtelli, W. Tong, M. Klang Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously Clin Cancer Res 9 2003 3578 3588
22. Y.K. Kim, J.W. Han, Y.N. Woo, J.K. Chun, J.Y. Yoo, E.J. Cho, S. Hong Activation of p21(WAF1/Cip1) transcription through Sp1 sites by histone deacetylase inhibitor apicidin: involvement of protein kinase C J Biol Chem 276 2001 42084 42090